• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

比较两种不同的 PEGylation 策略用于脂质体佐剂 CAF09:皮下疫苗接种后诱导 CTL 反应。

Comparison of two different PEGylation strategies for the liposomal adjuvant CAF09: Towards induction of CTL responses upon subcutaneous vaccine administration.

机构信息

Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 2, 2100 Copenhagen Ø, Denmark; Statens Serum Institut, Department of Infectious Disease Immunology, Artillerivej 5, 2300 Copenhagen S, Denmark.

Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Jagtvej 162, 2100 Copenhagen Ø, Denmark.

出版信息

Eur J Pharm Biopharm. 2019 Jul;140:29-39. doi: 10.1016/j.ejpb.2019.04.020. Epub 2019 May 2.

DOI:10.1016/j.ejpb.2019.04.020
PMID:31055066
Abstract

Using subunit vaccines, e.g., based on peptide or protein antigens, to teach the immune system to kill abnormal host cells via induction of cytotoxic T lymphocytes (CTL) is a promising strategy against intracellular infections and cancer. However, customized adjuvants are required to potentiate antigen-specific cellular immunity. One strong CTL-inducing adjuvant is the liposomal cationic adjuvant formulation (CAF)09, which is composed of dimethyldioctadecylammonium (DDA) bromide, monomycoloyl glycerol (MMG) analogue 1 and polyinosinic:polycytidylic acid [poly(I:C)]. However, this strong CTL induction requires intraperitoneal administration because the vaccine forms a depot at the site of injection (SOI) after subcutaneous (s.c.) or intramuscular (i.m.) injection, and depot formation impedes the crucial vaccine targeting to the cross-presenting dendritic cells (DCs) residing in the lymph nodes (LNs). The purpose of the present study was to investigate the effect of polyethylene glycol (PEG) grafting of CAF09 on the ability of the vaccine to induce antigen-specific CTL responses after s.c. administration. We hypothesized that steric stabilization and charge shielding of CAF09 by PEGylation may reduce depot formation at the SOI and enhance passive drainage to the LNs, eventually improving CTL induction. Hence, the vaccine (antigen/CAF09) was post-grafted with a novel type of anionic PEGylated peptides based on GDGDY repeats, which were end-conjugated with one or two PEG moieties, resulting in mono- and bis-PEG-peptides of different lengths (10, 15 and 20 amino acid residues). For comparison, CAF09 was also grafted by inclusion of 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy(PEG)-2000 (DSPE-PEG) in the bilayer structure during preparation. Grafting of CAF09 with either type of PEG resulted in charge shielding, evident from a reduced surface charge. Upon s.c. immunization of mice with the model antigen ovalbumin (OVA) adjuvanted with PEGylated CAF09, stronger CTL responses were induced as compared to immunization of mice with unadjuvanted OVA. Biodistribution studies confirmed that grafting of CAF09 with DSPE-PEG improved the passive drainage of the vaccine to LNs, because a higher dose fraction was recovered in DCs present in the draining LNs, as compared to the dose fraction detected for non-PEGylated CAF09. In conclusion, PEGylation of CAF09 may be a useful strategy for the design of an adjuvant, which induces CTL responses after s.c. and i.m. administration. In the present studies, CAF09 grafted with 10 mol% DSPE-PEG is the most promising of the tested adjuvants, but additional studies are required to further elucidate the potential of the strategy.

摘要

使用亚单位疫苗,例如基于肽或蛋白抗原的疫苗,来教导免疫系统通过诱导细胞毒性 T 淋巴细胞(CTL)来杀死异常宿主细胞,是一种针对细胞内感染和癌症的很有前途的策略。然而,需要定制佐剂来增强抗原特异性细胞免疫。一种强有力的 CTL 诱导佐剂是脂质阳离子佐剂制剂(CAF)09,它由二甲基二十八烷基溴化铵(DDA)、单酰基甘油(MMG)类似物 1 和聚肌苷酸:聚胞苷酸[聚(I:C)]组成。然而,这种强烈的 CTL 诱导需要腹腔内给药,因为疫苗在皮下(sc)或肌肉内(im)注射后在注射部位(SOI)形成储存库,而储存库的形成阻碍了疫苗对淋巴结(LN)中存在的交叉呈递树突状细胞(DC)的关键靶向作用。本研究的目的是研究 CAF09 的聚乙二醇(PEG)接枝对 sc 给药后疫苗诱导抗原特异性 CTL 反应能力的影响。我们假设 CAF09 的 PEG 化通过空间位阻和电荷屏蔽可以减少 SOI 处的储存库形成,并增强被动引流到 LNs,最终改善 CTL 诱导。因此,疫苗(抗原/CAF09)被新型基于 GDGDY 重复的阴离子 PEG 化肽进行了后接枝,其通过末端共轭连接一个或两个 PEG 部分,得到不同长度(10、15 和 20 个氨基酸残基)的单和双 PEG-肽。为了比较,CAF09 也在制备过程中通过包含 1,2-二硬脂酰-sn-甘油-3-磷酸乙醇胺-N-甲氧基(PEG)-2000(DSPE-PEG)在双层结构中进行接枝。CAF09 的接枝导致电荷屏蔽,从表面电荷的减少可以明显看出。用 PEG 化 CAF09 佐剂的模型抗原卵清蛋白(OVA)免疫小鼠后,与未佐剂的 OVA 免疫的小鼠相比,诱导了更强的 CTL 反应。生物分布研究证实,DSPE-PEG 接枝 CAF09 可改善疫苗向 LNs 的被动引流,因为在引流 LN 中存在的 DC 中回收的剂量分数更高,与检测到的非 PEG 化 CAF09 的剂量分数相比。总之,CAF09 的 PEG 化可能是一种有用的策略,用于设计可皮下和肌肉内给药后诱导 CTL 反应的佐剂。在本研究中,接枝 10 mol% DSPE-PEG 的 CAF09 是测试佐剂中最有前途的,但需要进一步研究来进一步阐明该策略的潜力。

相似文献

1
Comparison of two different PEGylation strategies for the liposomal adjuvant CAF09: Towards induction of CTL responses upon subcutaneous vaccine administration.比较两种不同的 PEGylation 策略用于脂质体佐剂 CAF09:皮下疫苗接种后诱导 CTL 反应。
Eur J Pharm Biopharm. 2019 Jul;140:29-39. doi: 10.1016/j.ejpb.2019.04.020. Epub 2019 May 2.
2
Induction of Cytotoxic T-Lymphocyte Responses Upon Subcutaneous Administration of a Subunit Vaccine Adjuvanted With an Emulsion Containing the Toll-Like Receptor 3 Ligand Poly(I:C).皮下给予含有 Toll 样受体 3 配体聚肌苷酸的乳剂佐剂的亚单位疫苗可诱导细胞毒性 T 淋巴细胞应答。
Front Immunol. 2018 Apr 30;9:898. doi: 10.3389/fimmu.2018.00898. eCollection 2018.
3
The administration route is decisive for the ability of the vaccine adjuvant CAF09 to induce antigen-specific CD8(+) T-cell responses: The immunological consequences of the biodistribution profile.给药途径对于疫苗佐剂CAF09诱导抗原特异性CD8(+) T细胞应答的能力具有决定性作用:生物分布特征的免疫学后果。
J Control Release. 2016 Oct 10;239:107-17. doi: 10.1016/j.jconrel.2016.08.034. Epub 2016 Aug 26.
4
Induction of CD8+ T-cell responses against subunit antigens by the novel cationic liposomal CAF09 adjuvant.新型阳离子脂质体CAF09佐剂诱导针对亚单位抗原的CD8 + T细胞应答。
Vaccine. 2014 Jun 30;32(31):3927-35. doi: 10.1016/j.vaccine.2014.05.050. Epub 2014 May 28.
5
PEGylated cationic liposomes robustly augment vaccine-induced immune responses: Role of lymphatic trafficking and biodistribution.聚乙二醇化阳离子脂质体可显著增强疫苗诱导的免疫应答:淋巴转运和生物分布的作用。
J Control Release. 2012 Apr 10;159(1):135-42. doi: 10.1016/j.jconrel.2011.12.017. Epub 2011 Dec 29.
6
A Highly Active Form of XCL1/Lymphotactin Functions as an Effective Adjuvant to Recruit Cross-Presenting Dendritic Cells for Induction of Effector and Memory CD8 T Cells.XCL1/Lymphotactin 的一种高活性形式可作为有效的佐剂,募集表达交叉呈递的树突状细胞,诱导效应和记忆性 CD8 T 细胞。
Front Immunol. 2018 Nov 27;9:2775. doi: 10.3389/fimmu.2018.02775. eCollection 2018.
7
Immunity by formulation design: induction of high CD8+ T-cell responses by poly(I:C) incorporated into the CAF01 adjuvant via a double emulsion method.通过配方设计实现免疫:通过双重乳液法将 Poly(I:C) 纳入 CAF01 佐剂中,诱导高 CD8+ T 细胞应答。
J Control Release. 2011 Mar 30;150(3):307-17. doi: 10.1016/j.jconrel.2010.11.021. Epub 2010 Nov 25.
8
Pegylation of DDA:TDB liposomal adjuvants reduces the vaccine depot effect and alters the Th1/Th2 immune responses.聚乙二醇化 DDA:TDB 脂质体佐剂可降低疫苗储库效应并改变 Th1/Th2 免疫应答。
J Control Release. 2012 Feb 28;158(1):72-7. doi: 10.1016/j.jconrel.2011.10.012. Epub 2011 Oct 18.
9
Cationic liposomes loaded with a synthetic long peptide and poly(I:C): a defined adjuvanted vaccine for induction of antigen-specific T cell cytotoxicity.负载合成长肽和聚肌苷酸-聚胞苷酸的阳离子脂质体:一种用于诱导抗原特异性T细胞细胞毒性的确定佐剂疫苗。
AAPS J. 2015 Jan;17(1):216-26. doi: 10.1208/s12248-014-9686-4. Epub 2014 Nov 12.
10
Th1 immune responses can be modulated by varying dimethyldioctadecylammonium and distearoyl-sn-glycero-3-phosphocholine content in liposomal adjuvants.Th1 免疫应答可以通过改变脂质体佐剂中二甲氨基十八烷基[二(十八烷酰基)]-氯化铵和二硬脂酰基-sn-甘油-3-磷酸胆碱的含量来调节。
J Pharm Pharmacol. 2014 Mar;66(3):358-66. doi: 10.1111/jphp.12173. Epub 2013 Nov 19.

引用本文的文献

1
Combination of Molecular Dynamics Simulations and Machine Learning Reveals Structural Characteristics of Stereochemistry-Specific Interdigitation of Synthetic Monomycoloyl Glycerol Analogs.分子动力学模拟与机器学习相结合揭示了合成单分枝菌酸甘油类似物立体化学特异性交叉指化的结构特征。
J Chem Inf Model. 2025 Jul 28;65(14):7605-7618. doi: 10.1021/acs.jcim.5c00615. Epub 2025 Jul 3.
2
Recent Advances in the Development of Mincle-Targeting Vaccine Adjuvants.靶向Mincle的疫苗佐剂开发的最新进展
Vaccines (Basel). 2024 Nov 26;12(12):1320. doi: 10.3390/vaccines12121320.
3
Liposomes, transfersomes and niosomes: production methods and their applications in the vaccinal field.
脂质体、传递体和非离子体:生产方法及其在疫苗领域的应用。
J Transl Med. 2024 Apr 9;22(1):339. doi: 10.1186/s12967-024-05160-4.
4
The Role of Mucoadhesion and Mucopenetration in the Immune Response Induced by Polymer-Based Mucosal Adjuvants.粘膜粘附和粘膜渗透在基于聚合物的粘膜佐剂诱导的免疫反应中的作用。
Polymers (Basel). 2023 Mar 24;15(7):1615. doi: 10.3390/polym15071615.
5
Recent progress on MHC-I epitope prediction in tumor immunotherapy.肿瘤免疫治疗中MHC-I表位预测的最新进展。
Am J Cancer Res. 2021 Jun 15;11(6):2401-2416. eCollection 2021.
6
Mimicking Pathogens to Augment the Potency of Liposomal Cancer Vaccines.模仿病原体以增强脂质体癌症疫苗的效力。
Pharmaceutics. 2021 Jun 24;13(7):954. doi: 10.3390/pharmaceutics13070954.
7
Cationic Nanoparticle-Based Cancer Vaccines.基于阳离子纳米颗粒的癌症疫苗
Pharmaceutics. 2021 Apr 21;13(5):596. doi: 10.3390/pharmaceutics13050596.
8
Applying Microfluidics for the Production of the Cationic Liposome-Based Vaccine Adjuvant CAF09b.应用微流控技术生产基于阳离子脂质体的疫苗佐剂CAF09b。
Pharmaceutics. 2020 Dec 19;12(12):1237. doi: 10.3390/pharmaceutics12121237.
9
Liposome Formulations as Adjuvants for Vaccines.脂质体配方作为疫苗佐剂。
Curr Top Microbiol Immunol. 2021;433:1-28. doi: 10.1007/82_2020_227.
10
The sixth revolution in pediatric vaccinology: immunoengineering and delivery systems.儿科疫苗学的第六次革命:免疫工程和传递系统。
Pediatr Res. 2021 May;89(6):1364-1372. doi: 10.1038/s41390-020-01112-y. Epub 2020 Sep 14.